Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2020-04-27 Proxy Solicitation & In…
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2020-04-27 English
FORM 4 SUBMISSION
Director's Dealing
2020-03-10 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 6, 2020, reporting a departure of a senior officer (Chief Medical Officer) and appointment of interim oversight by a board member. The key section is Item 5.02, which relates to departure and appointment of directors or certain officers. There is no financial data or report attached, and the document is a regulatory announcement of management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3260 characters, which is consistent with a brief announcement rather than a full report.
2020-03-09 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by AnaptysBio, Inc. on March 2, 2020. It registers additional shares under the company's 2017 Equity Incentive Plan and Employee Stock Purchase Plan. Form S-8 is a registration statement used for securities to be offered to employees under employee benefit plans. This is a capital markets filing related to share registration and issuance, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement itself. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is a full registration statement, not a brief announcement or certification.
2020-03-02 English
10-K
Annual Report FY 2019
2020-03-02 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 2, 2020, reporting the financial results for the three months and year ended December 31, 2019. It specifically mentions that a press release announcing these financial results is attached as an exhibit. The text states that the information is not "filed" for certain regulatory purposes and is primarily a current report announcing financial results. The document is short (4069 characters) and mainly serves to announce the earnings release rather than containing detailed financial statements or analysis itself. According to the classification rules, initial announcements of quarterly or periodical financial results (key highlights only) correspond to Earnings Release (ER).
2020-03-02 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.